Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: Results of a prospective phase 2 Spanish/PETHEMA trial

  • Mateos, M.V
  • Orio, A.
  • Rosiño, L.
  • Arriba, F.D.
  • Puig, N.
  • Martín, J.
  • Martínez-López, J.
  • Echeveste, M.A.
  • Sarrá, J.
  • Ocio, E.
  • Ramírez, G.
  • Martínez, R.
  • Palomera, L.
  • Payer, A.
  • Iglesias, R.
  • De Rubia, J.L.
  • Alegre, A.
  • Chinea, A.I.
  • Bladé, J.
  • Lahuerta, J.J.
  • Miguel, J.F S.
Bendamustine is a bifunctional alkylating agent with proven activity in myeloma. In this study 60 newly diag- nosed myeloma patients were given bendamustine plus bortezomib and prednisone in a regimen consisting of one cycle of bortezomib twice weekly for 6 weeks (1.3 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32), plus bendamus- tine (90 mg/m2 on days 1 and 4) and prednisone. The following cycles included bortezomib once weekly. Patients who were transplant candidates proceeded to stem cell collection after four cycles and the transplant was per- formed after six cycles. Patients who were not candidates for transplantation received up to nine cycles. Forty-two patients were transplant candidates and after six cycles, 50% achieved at least a very good partial response, with 24% having complete responses; 35 proceeded to a transplant, and the complete response rate was 54%. Seventeen patients continued up to nine cycles, and 57% achieved at least a very good partial response, including 26% with complete responses. The 2-year progression-free survival and overall survival rates were 62% and 86%, respectively. The safety profile was manageable, but stem cell mobilization was compromised in 35% of patients. In summary, this combination is effective in untreated patients, with an acceptable toxicity profile, but given the introduction of second-generation novel agents and monoclonal antibodies, the combination will probably be bet- ter reserved for relapsing patients, in whom stem cell collection is not needed, while cost-effective combinations with non-cross-resistant drugs continue to represent a medical need. This trial was registered with ClinicalTrials.gov, number NCT01376401.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials

  • Lopez-Anglada, L.
  • Cueto-Felgueroso, C.
  • Rosiñol, L.
  • Oriol, A.
  • Teruel, A.I.
  • Lopez de la Guia, A.
  • Bengoechea, E.
  • Palomera, L.
  • de Arriba, F.
  • Hernandez, J.M.
  • Granell, M.
  • Peñalver, F.J.
  • Garcia-Sanz, R.
  • Besalduch, J.
  • Gonzalez, Y.
  • Martinez, R.B.
  • Hernandez, M.T.
  • Gutierrez, N.C.
  • Puerta, P.
  • Valeri, A.
  • Paiva, B.
  • Blade, J.
  • Mateos, M.V.
  • Miguel, J.S.
  • Lahuerta, J.J.
  • Martinez-Lopez, J.
We investigated the prognostic impact and clinical utility of serum free light chains (sFLC) and serum heavy-light chains (sHLC) in patients with multiple myeloma treated according to the GEM2005MENOS65, GEM2005MAS65, and GEM2010MAS65 PETHEMA/GEM phase III clinical trials. Serum samples collected at diagnosis were retrospectively analyzed for sFLC (n = 623) and sHLC (n = 183). After induction or autologous transplantation, 309 and 89 samples respectively were available for sFLC and sHLC assays. At diagnosis, a highly abnormal (HA) sFLC ratio (sFLCr) (<0.03 or >32) was not associated with higher risk of progression. After therapy, persistence of involved-sFLC levels >100 mg/L implied worse survival (overall survival [OS], P = 0.03; progression-free survival [PFS], P = 0.007). Among patients that achieved a complete response, sFLCr normalization did not necessarily indicate a higher quality response. We conducted sHLC investigations for IgG and IgA MM. Absolute sHLC values were correlated with monoclonal protein levels measured with serum protein electrophoresis. At diagnosis, HA-sHLCrs (<0.29 or >73) showed a higher risk of progression (P = 0.006). Additionally, involved-sHLC levels >5 g/L after treatment were associated with shorter survival (OS, P = 0.001; PFS, P = 0.018). The HA-sHLCr could have prognostic value at diagnosis; absolute values of involved-sFLC >100 mg/L and involved-sHLC >5 g/L could have prognostic value after treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials

  • López-Anglada, Lucía|||0000-0003-1727-8546
  • Cueto-Felgueroso, Cecilia|||0000-0002-4329-9634
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Oriol, Albert|||0000-0001-6804-2221
  • Teruel, Ana Isabel|||0000-0003-1559-7607
  • López de la Guía, Ana|||0000-0002-7705-7844
  • Bengoechea, Enrique
  • Palomera, Luis|||0000-0003-0359-7191
  • De Arriba, Felipe|||0000-0002-4451-1318
  • Hernandez, Jose Mariano
  • Granell, Miquel|||0000-0002-0366-3673
  • Peñalver, Francisco Javier
  • García-Sanz, Ramón|||0000-0003-4120-2787
  • Besalduch, Joan
  • Gonzalez Montes, Yolanda|||0000-0002-4471-5142
  • Martinez, Rafael Benigno
  • Hernández, Miguel Teodoro|||0000-0002-6576-7881
  • Gutierrez, Norma C.
  • Puerta, Paloma
  • Valeri, Antonio
  • Paiva, Bruno|||0000-0003-1977-3815
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • Mateos, M. V.|||0000-0003-2390-1218
  • San Miguel, Jesús|||0000-0002-9183-4857
  • Lahuerta, J. J.|||0000-0002-3393-9570
  • Martínez-López, Joaquín|||0000-0001-7908-0063
We investigated the prognostic impact and clinical utility of serum free light chains (sFLC) and serum heavy-light chains (sHLC) in patients with multiple myeloma treated according to the GEM2005MENOS65, GEM2005MAS65, and GEM2010MAS65 PETHEMA/GEM phase III clinical trials. Serum samples collected at diagnosis were retrospectively analyzed for sFLC (n = 623) and sHLC (n = 183). After induction or autologous transplantation, 309 and 89 samples respectively were available for sFLC and sHLC assays. At diagnosis, a highly abnormal (HA) sFLC ratio (sFLCr) (<0.03 or.